
|Articles|April 21, 2015
KRAS and Outcomes in Pancreatic Cancer
Author(s)Mark Erlander, PhD
Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.
Advertisement
Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5

























